Scarica l'app Stockscreener
80.09
2.50%
-2.05
Bio Rad Laboratories Inc Borsa (BBIO) Ultime notizie
BIO|Bio Rad Laboratories Inc|Price:316.410|Chg%:+1.950 - TradingKey
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bio Rad Laboratories Inc (BIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio Rad Laboratories Inc (BIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BIO|Bio Rad Laboratories Inc|Price:314.460|Chg%:-1.760 - TradingKey
TradingKey - TradingKey
Bio-Rad Laboratories (BIO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Insight Molecular Diagnostics Ord Shs (IMDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bio-Rad Laboratories, Inc. (BIO) Stock forecasts - Yahoo Finance Singapore
Bio-Rad Laboratories (BIO) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Bio-Rad Laboratories Inc (BIO) Stock Up 3.4% and Still Undervalued -- GF Score: 72/100 - GuruFocus
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026 - BioSpace
Press Release: Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Moomoo
Bio-Rad will discuss Q2 results at 5 p.m. ET on Aug. 4 - Stock Titan
Bio-Rad to report Q2 2026 results, host conference call - Bitget
Bio-Rad Laboratories stock holds on to year-end earnings context - Ad-hoc-news.de
Bio-Rad Laboratories (BIO) Experiences Minor Decline Amid Compet - GuruFocus
Bio Rad Laboratories (BIO) Stock Looks Fairly Valued After A 57% Slide - Sahm
Bio-Rad Q1 2026 Earnings: EPS Misses Estimates by 5.68%, Stock Edges Higher on Resilient Business TrendsRevenue Breakdown Analysis - po-news-eg.net
Diagnostic Reagent Market is Going to Boom: New Report Reveals - openPR.com
(BIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
ETFs Investing in Bio-Rad Laboratories, Inc. Class A Stocks - TradingView
BIO5368763 Bond Coupon Profile — Rate & Payments - TradingView
BIO5368763 Bond Risk Profile - TradingView
BIO5368763 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Coupon Profile — Rate & Payments - TradingView
Bio-Rad unveils Vericheck ddPCR kits for QX700 QC - Select Science
Price to earnings forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate - Sahm
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 4.7% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad launches Vericheck ddPCR Kits compatible with QX700 platform for biopharma quality control and cell and gene therapy workflows - News-Medical
Bio-Rad Releases New Quality Control Kits for Cell and Gene Therapy - Clinical Lab Products
IVD Quality Control Market Size, Share | Industry Report [2034] - Fortune Business Insights
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential (NYSE:BIO) - Seeking Alpha
BIO Forecast — Price Target — Prediction for 2027 - TradingView
Price-Driven Insight from (BIO) for Rule-Based Strategy - Stock Traders Daily
2x Valuation Gap: BIO vs. CRL — Who’s Wrong? - NAI500
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - Yahoo Finance
In Fight With GC, Bio-Rad Adds Quinn Emanuel to Legal Team - Law.com
Bio-Rad Receives MicroVal Validation for Two EZ-Check Listeria Testing Kits - Quality Assurance & Food Safety
Bio-Rad receives microVal validation for EZ-CheckTM Listeria spp. and EZ-Check Listeria monocytogenes Testing Kits - Cambridge Network
Bio-Rad Laboratories (BIO) Surges 4.4% as Bullish Momentum Builds From Key Support LevelOBV Divergence - dars.gov.et
Is Elliott’s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)? - Yahoo Finance
Elliott Targets Bio-Rad After 70% Stock Collapse - Yahoo Finance
Elliott Stake Puts Bio-Rad Turnaround Plans And Sartorius Holding In Focus - Sahm
Elliott builds big stake in life-science firm Bio-Rad Labs, WSJ reports - MSN
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday - Benzinga
Elliott Management Takes Stake in Bio-Rad to Boost Stock Performance (BIO) - GuruFocus
Bio-Rad Expands Antibody Labeling Kits for Flow Cytometry and Western Blot - Clinical Lab Products
Morgan Stanley files Rule 144 notice to sell 550 BIO shares (NYSE: BIO) - Stock Titan
Bio‑Rad expands TrailBlazer kits for antibody conjugation to StarBright dyes - Select Science
Bio-Rad to Participate in Upcoming Investor ConferencesMay 8, 2026 - BioSpace
Ariel Investments Re-added Bio-Rad Laboratories (BIO) as Strong Margins and Market Leadership Stand Out - Yahoo Finance
Bio-Rad Navigates Academic Headwinds and Geopolitical Shifts in Q1 2026 Financial Results - Lab Manager
Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
Bio-Rad drops 10.2% as guidance cut and Sartorius valuation hit overshadow Q1 results - Quiver Quantitative
Bio-Rad introduces the PTC Harmony 96 and PTC Harmony Deepwell thermal cyclers - Select Science
Liquidity Mapping Around (BIO) Price Events - Stock Traders Daily
Bio-Rad launches PTC Harmony 96 and PTC Harmony Deepwell Thermal Cyclers - News-Medical
Saudi Arabia In-Vitro Diagnostics (IVD) Market Report - GlobeNewswire
Bio-Rad Laboratories, Inc. (BIO) PT Reduced to $300 by Citigroup Amid Process Chromatography Concerns - Yahoo Finance
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026 - Business Wire
Bio-Rad extends range of anti-idiotypic antibodies and anti-Fc mutation antibodies for bioanalysis and drug monitoring - News-Medical
Understanding the new MIQE 2.0 Guidelines for qPCR - Labroots
Nanditha Yelamanchi Appointed as EVP & Chief Human Resources Officer at Bio-Rad Laboratories - hrtoday.in
Disappointing Results Hurt Bio-Rad Laboratories (BIO) - Yahoo Finance
Discipline and Rules-Based Execution in BIO Response - Stock Traders Daily
1.04%
11.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):